A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy of a single dose of baloxavir marboxil in the prevention of influenza virus infection
Phase of Trial: Phase III
Latest Information Update: 02 Sep 2019
Price : $35 *
At a glance
- Drugs Baloxavir-marboxil (Primary)
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Acronyms BLOCKSTONE
- Sponsors Shionogi
- 02 Sep 2019 According to an Genentech media release, this study is the first to show that Xofluza is an effective preventive treatment following exposure to the flu and the company looks forward to sharing these data with health authorities.
- 02 Sep 2019 According to an Genentech media release, full results of the study were presented as a late-breaking abstract during the OPTIONS X 2019 congress in Singapore(Abstract #11718).
- 02 Sep 2019 Results published in the Genentech Media Release.